LAVAL, Quebec, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Acasti Pharma ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), a subsidiary of Neptune Technologies & Bioressources Inc., announces the appointment of Reed V. Tuckson, M.D. to its Board of Directors. Dr. Tuckson's appointment increases Acasti's Board to 6 members, 4 of whom are independent directors.
"Dr. Tuckson is a recognized leader in his field," highlighted Mr. Henri Harland, President and CEO of Acasti. "He brings a strong reputation, deep industry knowledge and valuable insight into health and medical care, including the translation of science and technology into clinical interventions. We look forward to his leadership in supporting and communicating our science-based research and drug development activities on omega-3 phospholipids."
"Throughout my career, whether as Commissioner of Public Health for the District of Columbia, as Chief of Medical Affairs for the largest health insurer in the United States, or as Managing Director of Tuckson Health Connections, I have always sought to bring the most effective health solutions to the greatest possible number of people," said Dr. Tuckson. "The differentiated benefits of omega-3 phospholipids for pharmaceutical applications are becoming better understood and I am excited about the opportunities ahead for Acasti and its prescription drug candidate, CaPre ®. I believe that CaPre ® has the potential to make a real difference in cardiovascular care for people worldwide. I look forward to joining Acasti's Board and supporting and communicating the developments that continue to be key to the Corporation's continued success."Dr. Tuckson is currently the Managing Director of Tuckson Health Connections, LLC, a health and medical care consulting business. Previously, he served a long tenure as Executive Vice President and Chief of Medical Affairs for UnitedHealth Group, a Fortune 25 health and wellbeing company, which includes the United States largest health insurer and the industry's most comprehensive health services company.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts